Millions of babies and children undergo anaesthesia every year. Preclinical evidence shows that all common anaesthetic drugs are associated with neuro-apoptosis and neurodevelopmental deficits in immature rodent models. Xenon, a low-potency anaesthetic gas, renowned for producing cardiostable anaesthesia and with neuroprotective properties in multiple pathologies, was recently used to reduce sevoflurane requirements of babies and young children undergoing cardiac catheterisation. Preclinical studies have shown the addition of xenon reduced neuroapoptosis induced by 0.7% isoflurane in vivo and in vitro.
Recent Posts
- A Scoping Review of the Mechanisms Underlying Developmental Anesthetic Neurotoxicity
- 2025 Annual Meeting, presented by the International Anesthesia Research Society (IARS) and the Society of Critical Care Anesthesiologists (SOCCA), March 20 – 23, 2025, Honolulu, HI
- Exposure to Operative Anesthesia in Childhood and Subsequent Neurobehavioral Diagnoses: A Natural Experiment Using Appendectomy
- Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial. Claire Elizabeth Wainwright, et al. June 2024
- Columbia University Physician Scientist and SmartTots Investigator, Caleb Ing, MD, publishes new findings regarding prenatal exposure to general anesthesia and subsequent risk to the child.